Table 2.
Clinicopathological parameters analysis according to rs2228014 CXCR4 genetic polymorphism in breast cancer patients.
|
Total N (%) |
CXCR4 genotype | p value | |||
|---|---|---|---|---|---|
| CC | Allele T carrier | ||||
| N (%) | N (%) | ||||
| Tumor histologya | IDC | 45 (90.0) | 40 (80.0) | 05 (10.0) | 0.686 |
| ILC | 02 (4.0) | 01 (2.0) | 01 (2.0) | ||
| Others | 03 (6.0) | 03 (6.0) | 00 (0.0) | ||
|
| |||||
| Nuclear grade | I | 11 (22.0) | 08 (17.4) | 03 (6.5) | 0.312 |
| II | 16 (34.7) | 14 (30.4) | 02 (4.3) | ||
| III | 19 (41.3) | 19 (41.3) | 00 (0.0) | ||
|
| |||||
| Nodal status | Negative | 27 (60.0) | 22 (48.9) | 05 (11.1) | 0.697 |
| Positive | 18 (40.0) | 17 (37.8) | 01 (2.2) | ||
|
| |||||
| ER status | Negative | 06 (12.5) | 06 (12.5) | 00 (0.0) | 0.630 |
| Positive | 42 (87.5) | 36 (75.0) | 06 (12.5) | ||
|
| |||||
| PR status | Negative | 10 (20.8) | 10 (20.8) | 00 (0.0) | 0.287 |
| Positive | 38 (79.2) | 32 (66.7) | 06 (12.5) | ||
|
| |||||
| p53 | Negative | 33 (75.0) | 27 (61.4) | 06 (13.6) | 0.789 |
| Positive | 11 (25.0) | 11 (25.0) | 00 (0.0) | ||
|
| |||||
| Ki67 | Low | 17 (44.8) | 12 (31.6) | 05 (13.2) | 0.129 |
| Moderate | 05 (13.1) | 04 (10.5) | 01 (2.6) | ||
| High | 18 (42.1) | 16 (42.1) | 00 (0.0) | ||
|
| |||||
| HER2 | Negative | 32 (71.1) | 27 (60.0) | 05 (11.1) | 0.818 |
| Positive | 13 (28.9) | 12 (26.7) | 01 (2.2) | ||
aIDC: Invasive Ductal Carcinoma; ILC: Invasive Lobular Carcinoma; others: CMI, ductal carcinoma in situ.